Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04163419 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
A Phase 2 study of Pain and Schwannomatosis, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT04163419: Active Phase 2 study of Pain and Schwannomatosis, sponsored by Massachusetts General Hospital.
NCT04163419 is a Phase 2 study of Pain and Schwannomatosis that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 9 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04163419, a Phase 2 study of Pain and Schwannomatosis, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to determine whether the administration of tanezumab, an anti-nerve growth factor (NGF) antibody, improves pain relief in schwannomatosis patients receiving background non-NSAID therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tanezumab
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-04-30 |
| Est. Completion | 2024-09-30 |
| Phase | Phase 2 |
What the registry record for NCT04163419 still lists
NCT04163419 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04163419 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04163419 about?
NCT04163419 is a clinical study titled "Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis". The primary objective of this study is to determine whether the administration of tanezumab, an anti-nerve growth factor (NGF) antibody, improves pain relief in schwannomatosis patients receiving background non-NSAID therapy.
What is the current status of trial NCT04163419?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-04-30. Estimated completion is 2024-09-30.
What conditions does trial NCT04163419 study?
This clinical trial studies the following conditions: Pain, Schwannomatosis.
What interventions are being tested in trial NCT04163419?
The interventions under investigation include: Placebo (DRUG), Tanezumab (DRUG).
Who is sponsoring clinical trial NCT04163419?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04163419 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04163419's enrollment target sits among peer trials
9 368th of 374 higher than 4 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Neural Correlates of Hypoalgesia Driven by Observation
RECRUITING · Phase 2
-
Cannabis for Palliative Care in Cancer
RECRUITING · Phase 2
-
Pain After Buffered Vs Non Buffered Articaine
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI